- support
- info@evidentic.com
- +49 (0) 30 959 99 8831
Menu
Therapeutic Aflibercept fusion antibody from the original Eylea® commercial drug.
Showing all 3 results
ProductBatch | Antigen | Molecular Class | Drug Brand | Product Concentration | CoA | Quantity per vial | Storage Temperature | Expiry Date | Price from | |
|---|---|---|---|---|---|---|---|---|---|---|
PlGF , VEGF-A , VEGF-B |
Fusion protein |
Zaltrap® |
25 mg/mL |
– |
2 mg |
tba |
tba |
197,00 € |
||
PIGF , VEGF-A |
Fusion protein |
Eylea® |
40 mg/mL |
– |
0,8 mg |
-80°C |
11/2021 |
548,10 € |
||
PIGF , VEGF-A |
Fusion protein |
Eylea® |
40 mg/mL |
– |
0,8 mg |
-80°C |
02/2025 |
1.011,00 € |
| Drug name | Eylea® |
| INN | Aflibercept |
| API type | Fusion protein consisting of portions of human VEGF (Vascular Endothelial Growth Factor) receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 and produced in Chinese hamster ovary (CHO) K1 cells by recombinant DNA technology |
| Pharmacotherapeutic group | Ophthalmologicals / Antineovascularisation agents |
| ATC code | S01LA05 |
| Target of antibody | Vascular endothelial growth factor A (VEGF-A) and placental growth factor (PlGF) |
| General function | Aflibercept is an engineered protein that has been designed to attach to and block the effects of a substance called vascular endothelial growth factor A (VEGF-A). It can also attach to other proteins such as placental growth factor (PlGF). VEGF-A and PlGF are involved in stimulating the abnormal growth of blood vessels in patients with AMD, certain types of macular oedema and myopic choroidal neovascularisation. By blocking these factors, aflibercept reduces the growth of the blood vessels and controls the leakage and swelling. |
| Short description | |
| Pharmacodynamic properties (Mechanism of action; Source EMA document) | Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptor 1 and 2 extracellular domains fused to the Fc portion of human IgG1. Aflibercept acts as a soluble decoy receptor that binds VEGF-A and PlGF with higher affinity than their natural receptors, and thereby can inhibit the binding and activation of these cognate VEGF receptors. |
| Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document) | Wet AMD is characterised by pathological choroidal neovascularisation (CNV). Leakage of blood and fluid from CNV may cause retinal thickening or oedema and/or sub-/intra-retinal haemorrhage, resulting in loss of visual acuity. In patients treated with Eylea, central retinal thickness [CRT] decreased soon after treatment initiation, and the mean CNV lesion size was reduced. |
| Original license holder | Bayer AG Müllerstraße 178 13353 Berlin Germany |
| Marketing authorisation numbers | EU/1/12/797/002 |
| Marketing authorisation holder | Bayer AG 51368 Leverkusen Germany |
| Name of the manufacturer of the biological active substance | Regeneron Pharmaceuticals, Inc. 81 Columbia Turnpike Rensselaer, New York 12144 USA |
| Name and address of the manufacturer(s) responsible for batch release | Bayer AG Müllerstraße 178 13353 Berlin Germany |
| Max shelf life | 24 months |
| Storage conditions | 2°C – 8°C |
| List of excipients | Polysorbate 20 Sodium dihydrogen phosphate, monohydrate Disodium hydrogen phosphate, heptahydrate Sodium chloride Sucrose |
Evidentic GmbH
Martin-Buber-Str. 10
14163 Berlin
